Bessemer Group
SMMT icon

Bessemer Group’s Summit Therapeutics SMMT Stock Holding History

Bessemer Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Hold
135
– – ﹤0.01% 2427
2026
Q1 		$3K Sell
135
-880
-87% -$14.2K ﹤0.01% 2332
2025
Q4 		$17K Buy
1,015
+880
+652% +$16.6K ﹤0.01% 1940
2025
Q3 		$3K Hold
135
– – ﹤0.01% 2266
2025
Q2 		$3K Hold
135
– – ﹤0.01% 2153
2025
Q1 		$3K Sell
135
-10
-7% -$201 ﹤0.01% 2178
2024
Q4 		$3K Hold
145
– – ﹤0.01% 2157
2024
Q3 		$3K Buy
+145
New +$2.03K ﹤0.01% 2126

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bessemer Group's SMMT Position: Q2 2026 in Review

Bessemer Group held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 135 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #2427.

Bessemer Group first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $17K in Q4 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Bessemer Group held 135 shares of Summit Therapeutics worth $2K as of Q2 2026.
  • Bessemer Group left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2427 holding.
  • Bessemer Group first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Bessemer Group's Summit Therapeutics position peaked at $17K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.